

## Notice Regarding Recalculated 340B Price for Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. has identified the below product was offered at an incorrect 340B Price. Amphastar has asked the Office of Pharmacy Affairs (OPA) to post this Notice on the OPA's public website to ensure transparency by providing access to information about Amphastar's recalculation and potential overpayment by certain 340B Covered Entities for this impacted Amphastar product.

340B Covered Entities that purchased this NDC during the timeframe January 1, 2019 – June 30, 2019, and were charged more than the 340B correct price, will receive a refund equal to the difference between the 340B correct price and the price that the Covered Entity purchased the product during this timeframe.

Amphastar Pharmaceuticals, Inc. will reach out to each affected Covered Entity identified as entitled to a refund. Additionally, any entity who believes they are entitled to this refund may also send an email to [info@amphastar.com](mailto:info@amphastar.com) with "Entity Name for 340B Refund" in the subject line in order for Amphastar to process a refund accordingly.

<b>NDC Number</b>	<b>Product Description</b>
00548-5900-00	Cortrosyn <sup>®</sup> (Cosyntropin for Injection USP) 0.25 mg Vial